Session X: Aggressive B-Cell Lymphoma 

Session Chairs: Ann LaCasce, MD, MMSc and Juan Alderuccio, MD

Selecting Frontline Therapy for DLBCL: The Role of FISH, GEP and Genomic Classifiers | Brian T. Hill, MD, PhD | Cleveland Clinic, Cleveland, Ohio, USA

Update on Second-Line Approaches to R/R DLBCL | Elizabeth Budde, MD, PhD | City of Hope, Duarte, California, USA

Beyond CAR T-Cell Therapy and Bispecifics- Strategies for Treating R/R DLBCL | Juan Alderuccio, MD | Sylvester Comprehensive Cancer Center, Miami, Florida, USA

Novel Approaches to Managing Elderly and Unfit Patients With DLBCL | Pallawi Torka, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Optimizing Therapy of PMBCL in the Modern Era | Ann LaCasce, MD, MMSc | Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Practical Management of CAR T-Cell Therapy and Bispecific Antibody Toxicities | Michael Jain, MD, PhD | H. Lee Moffitt Cancer Center, Tampa, Florida, USA

Oral Abstract | TBD | Speaker | Affiliation